Company Description
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders.
Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.
The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials.
In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders.
Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
| Country | United States |
| Founded | 2017 |
| IPO Date | Mar 26, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 88 |
| CEO | Dr. Kevin Koch Ph.D. |
Contact Details
Address: 1715 38th St Boulder, Colorado 80301 United States | |
| Phone | 720-262-7002 |
| Website | edgewisetx.com |
Stock Details
| Ticker Symbol | EWTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001710072 |
| CUSIP Number | 28036F105 |
| ISIN Number | US28036F1057 |
| Employer ID | 82-1725586 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Peter A. Thompson FACP, M.D. | Co-Founder and Independent Chairman |
| Dr. Kevin Koch Ph.D. | President, Chief Executive Officer and Director |
| Dr. Badreddin Edris Ph.D. | Co-Founder and Independent Director |
| Dr. Alan J. Russell Ph.D. | Co-Founder, Chief Scientific Officer and Director |
| Dr. Joanne M. Donovan M.D., Ph.D. | Chief Medical Officer |
| R. Michael Carruthers | Chief Financial Officer |
| John R. Moore | General Counsel |
| Dr. Behrad Derakhshan Ph.D. | Chief Business Officer |
| Dr. Marc Semigran M.D. | Chief Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 10, 2024 | 8-K | Current Report |
| May 10, 2024 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
| May 9, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| May 9, 2024 | 10-Q | Quarterly Report |
| May 9, 2024 | 8-K | Current Report |
| May 7, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 7, 2024 | 8-K | Current Report |
| Apr 26, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 26, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 15, 2024 | PRE 14A | Other preliminary proxy statements |